Genetron (GTH) Stock Price, News & Analysis

Company Overview

Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.

Key Stats

• Today's Range: $4.02 to $4.05
• 50-Day Range: $3.85 to $4.03
• 52-Week Range: $2.08 to $4.05
• Volume: 412,603 shs
• Average Volume: 51,662 shs
• Market Capitalization: $127.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GTH Stock Analysis - Frequently Asked Questions

How were Genetron's earnings last quarter?

Genetron Holdings Limited (NASDAQ:GTH) posted its quarterly earnings data on Sunday, May, 23rd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.30. The business had revenue of $14.05 million for the quarter.

When did Genetron's stock split?

Genetron's stock reverse split before market open on Thursday, October 26th 2023.The 1-3 reverse split was announced on Thursday, October 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

When did Genetron IPO?

Genetron (GTH) raised $162 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 13,000,000 shares at $11.50-$13.50 per share. Credit Suisse and CICC served as the underwriters for the IPO and BTIG and Canaccord Genuity were co-managers.

What other stocks do shareholders of Genetron own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genetron investors own include NVIDIA (NVDA), ServiceNow (NOW), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD), Meta Platforms (META) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/23/2021
• Today: 10/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GTH
• CIK: 1782594
• Web: www.genetronhealth.com
• Phone: 86-10-5090-7500
• Fax: N/A
• Employees: 993
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $94.34 million
• Price / Sales: 1.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.63 per share
• Price / Book: 1.53

Miscellaneous

• Outstanding Shares: 31,620,000
• Free Float: N/A
• Market Cap: $127.27 million
• Optionable: Not Optionable
• Beta: 0.51